Postes actifs de Richard A. Markus
Sociétés | Poste | Début | Fin |
---|---|---|---|
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | Directeur/Membre du Conseil | - | - |
Directeur Général | - | - | |
President | - | - |
Historique de carrière de Richard A. Markus
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Chief Executive Officer | 1 |
President | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | Health Technology |
- Bourse
- Insiders
- Richard A. Markus
- Expérience